Vaccines & Disease · COVID-19

Who is at highest risk for complications from the COVID-19 vaccine?

Published November 8, 2021 · 1 min read
01

Outstanding Safety Concerns

Antibody Dependent Enhancement (Disease Enhancement)

For the past two decades, coronavirus vaccine research has been hampered by one consistent adverse outcome in particular – paradoxical immune enhancement or disease enhancement. This occurs because coronaviruses produce two different types of antibodies—neutralizing antibodies that fight the infection, and binding antibodies (or non-neutralizing antibodies) that cannot prevent viral infection. Incapable of preventing viral infection, binding antibodies can instead trigger paradoxical immune enhancement. This means that a person may seem fine until they contract the illness, and when this occurs, the disease is much more severe than it would have otherwise been.

In the FDA briefings issued at the December 2020 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meetings for both the Pfizer-BioNTech and Moderna COVID-19 vaccines, the agency reported that:

“Available data do not indicate a risk of vaccine-enhanced disease, and conversely suggest effectiveness against severe disease within the available follow-up period. However, risk of vaccine-enhanced disease over time, potentially associated with waning immunity, remains unknown and needs to be evaluated further in ongoing clinical trials and in observational studies that could be conducted following authorization and/or licensure.”

This information was also included in the Janssen/Johnson & Johnson FDA briefing document presented at the February 26, 2021 VRBPAC meeting in advance of the emergency use authorization approval.

Select disease / vaccine